Immuron Ltd ADR is a biopharmaceutical company dedicated to developing innovative oral immunotherapy solutions harnessing polyclonal antibodies to treat infectious and immunomodulated diseases. Operating globally with research and development activities based in Australia and the United States, Immuron is headquartered in Carlton, Australia. The company is focused on utilizing its proprietary technologies to improve patient outcomes while strategically expanding its product pipeline, positioning itself competitively within the biopharmaceutical sector.